Potential benefits of heterologous mixture of COVID 19 vaccinations from different manufacturers

Abstract

The ongoing COVID-19 pandemic has been going on since 2019 and has spread throughout the world’s region. To fight of COVID-19 virus, different vaccine Manufacturer Company has come up with different types of vaccines that include AstraZeneca, Pfizer/BNT Moderna, Sinovac etc. Vaccines are comprised of two vaccine regimens, the initial dose as prime dose and the second dose shot as a booster dose. A booster dose is important to produce enough antibodies to neutralize the COVID-19 virus. In the meantime, the virus has mutated several times and became more deadly. This study finds that a better immune response can be generated if two different types of vaccines are mixed and used as an initial and second dose. The immune system produces more virus-killing antibodies than single-brand vaccines used as an initial and subsequent dose. The side effects of such vaccination are found quite normal. The issue of vaccine shortage can also be overcome by such mixed vaccination. Some countries have failed to secure the buy of a single brand vaccine in large numbers, they can provide the second and further doses with the vaccine they have in their inventory in such vaccination procedure. They will have an option to provide a second dose with a different brand vaccine if they face any potential vaccine shortage. Heterologous vaccination will prove additional security from the new and deadly COVID-19 variants with enhanced immune protection as interpreted by some research.